Microbot Medical Stock Z Score

Understanding the fundamental principles of building solid financial models for Microbot Medical is extremely important. It helps to project a fair market value of Microbot Stock properly, considering its historical fundamentals such as Z Score. Since Microbot Medical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Microbot Medical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Microbot Medical's interrelated accounts and indicators.

To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.

Based on the company's disclosures, Microbot Medical has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.

We derive many important indicators used in calculating different scores of Microbot Medical from analyzing Microbot Medical's financial statements. These drivers represent accounts that assess Microbot Medical's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Microbot Medical's important valuation drivers and their relationship over time.

The Macroaxis Fundamental Analysis modules help investors analyze Microbot Medical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Microbot Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Microbot Medical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.